News: prostate cancer
SAiGENCI researchers given a funding boost
Researchers from the South ÐÓ°ÉÖ±²¥n immunoGENomics Cancer Institute (SAiGENCI), based at the ÐÓ°ÉÖ±²¥ of Adelaide, have been awarded funding to further their work in prostate and pancreatic cancers.
[Read more about SAiGENCI researchers given a funding boost]
Movember and SAiGENCI partner on landmark database to drive improvements in prostate cancer care
, the leading global men’s health charity, has partnered with the South ÐÓ°ÉÖ±²¥n immunoGENomics Cancer Institute (SAiGENCI) at the ÐÓ°ÉÖ±²¥ of Adelaide, to create a transformative database that will help researchers develop strategies for clinicians to personalise decisions about prostate cancer care.
Unlocking the mysteries of prostate cancer
The SAiGENCI team is creating a comprehensive data repository and applying machine learning to uncover revolutionary insights for prostate cancer treatment and prevention.
[Read more about Unlocking the mysteries of prostate cancer]
ENZAMET shows promise as prostate cancer treatment
The results from the clinical trial of ENZAMET, co-chaired by Professor Christopher Sweeney, Director of the South ÐÓ°ÉÖ±²¥n immunoGENomics Cancer Institute (SAiGENCI) that operates within the ÐÓ°ÉÖ±²¥ of Adelaide, have been published today in .
[Read more about ENZAMET shows promise as prostate cancer treatment ]
![RSS News Feed](/global/images/rss.gif" "RSS News Feed"){kind=small}